Legitimate Facts On Our CAL-101 Achievements

A case report form was completed for each subject with medication information recorded by a nurse. Blood samples were drawn from an antecubital vein using Vacutainer tubes. The samples were collected and handled according to hospital routines. TG, total cholesterol and high-density lipoprotein (HDL)-C plasma concentrations were measured by enzymatic peroxidase reaction, using a Roche Diagnostics Ltd Cobas? 6000 (c501module). Plasma LDL-C was calculated by Friedewalds formula [18], and apolipoprotein (apo)A1 and apoB were measured by an immunoturbidometric http://www.selleckchem.com/products/bay-57-1293.html method [19] at the Centre for Laboratory Medicine at Uppsala University Hospital. Glucose was measured by UV test, an enzymatic hexokinase reference method, developed by Roche Diagnostics using the Cobas? 6000 analyzer. Plasma insulin was measured by an enzyme-linked immunoassay kit (Mercodia AB, Uppsala, Sweden). Homeostasis model assessment-insulin resistance (HOMA-IR) was calculated as plasma insulin?��?glucose/22.5 [20]. Plasma high-sensitivity C-reactive protein (CRP) was measured by an immunological particle enhanced reaction, developed by Roche Diagnostics, using the Cobas? 6000 analyzer. Data are presented as mean?��?SD. Per protocol analysis was used to assess effects on outcome measures. Variables not normally distributed were logarithmically transformed. Paired t-test was used to assess change within groups http://www.selleckchem.com/products/gsk2126458.html and unpaired t-tests to compare mean changes between groups. It was estimated that 92 subjects were required for 80% power with a type I error of 5% to detect a difference of 0.25?mmol?L?1 in plasma LDL-C levels with an SD of ��0.56?mmol?L?1. In secondary analyses, we also tested within-group changes and between-group differences during follow-up using ancova, with baseline values and weight change as covariates; t-tests http://www.selleck.cn/products/CAL-101.html were two-tailed, and P?